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ABSTRACT
The p53 tumor suppressor protein plays a crucial role in influencing cell fate 
decisions in response to cellular stress. As p53 elicits cell cycle arrest, senescence 
or apoptosis, the integrity of the p53 pathway is considered a key determinant of 
anti-tumor responses. p53 can also promote autophagy, however the role of p53-
dependent autophagy in chemosensitivity is poorly understood. VMY-1-103 (VMY), 
a dansylated analog of purvalanol B, displays rapid and potent anti-tumor activities, 
however the pathways by which VMY works are not fully defined. Using established 
prostate cancer cell lines and novel conditionally reprogrammed cells (CRCs) derived 
from prostate cancer patients; we have defined the mechanisms of VMY-induced 
prostate cancer cell death. Herein, we show that the cytotoxic effects of VMY required 
a p53-dependent induction of autophagy, and that inhibition of autophagy abrogated 
VMY-induced cell death. Cancer cell lines harboring p53 missense mutations evaded 
VMY toxicity and treatment with a small molecule compound that restores p53 activity 
re-established VMY-induced cell death. The elucidation of the molecular mechanisms 
governing VMY-dependent cell death in cell lines, and importantly in CRCs, provides 
the rationale for clinical studies of VMY, alone or in combination with p53 reactivating 
compounds, in human prostate cancer.
INTRODUCTION
The efficacy of anti-tumor agents relies on 
their ability to trigger cellular programs of apoptosis, 
senescence and mitotic catastrophe that lead to cell 
death. Impairment of apoptosis confers resistance to 
tumor therapy and may contribute to disease progression 
and recurrence. Several studies suggest, however, that 
apoptosis per se is the not only, or even the predominant, 
mechanism of cell death during chemotherapy [1-4]. 
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Among the alternative mechanisms, autophagy, either 
concomitantly with- or independently- of apoptosis, 
is emerging as an important pro-cell death, anti-tumor 
pathway. 
Autophagy is a degradative process by which 
damaged cellular organelles and abnormally folded 
proteins are cleared via the lysosome [5-7]. Autophagy 
may participate in either tumor suppressive or 
collaborative oncogenic signaling [8, 9]. In normal 
tissues and in many tumor cells, autophagy enables 
adaptation during nutritional stress via the degradation 
of macromolecules and intracellular organelles, thereby 
promoting cancer cell proliferation. In contrast, the 
impairment of autophagy can promote malignant 
transformation, as the mono-allelic deletion of Beclin-1 
or loss of heterozygosity of several autophagic genes 
occurs in human tumors [5, 10, 11]. Multiple myeloma 
cells succumb to excessive autophagic activation triggered 
by inhibition of caspase 10 [12] and, we have shown 
that autophagy induced by glucose restriction [13] or by 
inhibitors of the mitochondrial transporter SLC25A1/CIC 
[14] can be directly responsible for cell death.
The activity of the p53 tumor suppressor gene is 
induced by a broad array of cell stressors including DNA-
damaging chemotherapeutic drugs and can be an excellent 
target for therapeutic intervention [15]. While the role of 
p53 in regulating apoptosis is well documented, various 
lines of evidence suggest that p53 and autophagy are 
also closely connected, although in a complex and at 
times conflicting manner. Pharmacological inhibition or 
ablation of p53 can enhance autophagy during nutrient 
stress and hypoxia [8], contributing to cell survival [16]. 
However, autophagy stabilizes p53 [17], resulting in a 
feed-forward activation of p53-dependent autophagy 
and cell death following DNA damage. p53 can also 
induce autophagy via inhibiting mTOR (reviewed in [18, 
19]). Understanding the role of p53 to either induce or 
inhibit autophagy is important in determining therapeutic 
outcomes and based on these and other studies, we and 
others have proposed that autophagy contributes to the 
ability of p53 to eliminate cells that have been exposed 
to genotoxic stressors, preserving cellular and genomic 
integrity [9, 20, 21].
One obstacle to the development of new prostate 
cancer therapeutics has been the inability to establish 
sustained cultures of primary normal prostate and prostate 
cancer cells derived from patients. We have developed 
a novel culture methodology, termed “conditional 
reprogrammed cells” (termed CRCs), that provides an 
epithelial cell culture environment that facilitates the 
bypassing of replicative senescence, with the epithelial 
cells becoming reversibly immortalized without detectable 
cell crisis [22-25]. The ability to rapidly generate primary 
human cell cultures provides a unique opportunity to 
define the genetic and molecular basis of prostate cancer 
and to establish a framework for the personalization of 
therapy. This unique approach has been integrated into the 
present study.
The in vitro [26-28] and in vivo [29] anti-tumor 
activities of a novel CDK inhibitor, VMY-1-103 (VMY), 
were previously described, and VMY induces p53 activity 
and apoptosis in the wild type p53 prostate cancer cell line, 
LNCaP [26]. In the present study, we sought to define the 
molecular and genetic mechanisms of VMY-induced cell 
death. Herein we show that both prostate cancer (PCa) cell 
lines and primary prostate cancer CRCs with wild-type 
p53, were highly sensitive to VMY-induced cell death and 
occurred via the activation of macro-autophagy. p53 null 
or p53 mutant cell lines were insensitive to VMY-induced 
cytotoxicity. Furthermore, although p53 mutant expressing 
cells were resistant to VMY cytotoxicity, co-treatment 
of these cell lines with the p53-reactivating compound 
PRIMA-1, which restores wild-type p53 activity, re-
sensitized these otherwise resistant cells to VMY-induced 
cell death. Mutation of the p53 gene occurs relatively 
infrequently (20%) in early stage prostate cancers but 
increases significantly in late stage and metastatic PCa 
[30]. Given that small molecules that reactivate mutant 
p53 are currently in clinical trials, we propose that VMY 
in combination with such reactivating molecules may 
provide a potentially effective cancer therapeutic in both 
the early and late stages of PCa.
 RESULTS
VMY induces cell death in p53 wild-type cancer 
cell lines
To further clarify whether wild-type p53 is required 
for VMY-induced cell death, we interrogated cell lines 
derived from a distinct tissue types and differing in p53 
status. VMY induced a G
2
/M arrest as assessed by flow 
cytometry, regardless of p53 status (Fig. 1A), indicating 
that this compound affects the cell cycle in a p53-
independent manner. Many cells lacking functional p53 
retain the capability to arrest in G2/M [31]. In contrast, 
the percentage of cells detected in the subG1 phase of the 
cell cycle, indicative of apoptosis, was higher in all of the 
cell lines harboring wild-type p53 versus cells with a p53 
-null or -mutant genotype. LNCaP and MCF7 and DU145 
and PC3 were used as positive and negative controls, 
respectively [26, 32]. Consistent with our previous data 
[26], VMY induced wild-type, but not mutant, p53 protein 
levels across multiple cell lines and tissue types (Fig. 1B), 
which correlated with VMY-induced subG1 content (Fig. 
1A).
Using flow cytometry, early apoptosis was measured 
by annexin V immunostaining. Propidium iodide (PI) 
positive, necrotic cells were excluded from these analyses. 
The basal levels of annexin V were uniformly higher in 
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the p53 wild-type cells versus p53-null or p53-mutant cell 
lines. Treatment with VMY increased annexin positivity 
in p53 wild-type cells (Fig. 1C). Thus, wild-type p53 
appears to be an important transducer of VMY's effects 
on apoptosis.
Wild-type p53 is necessary for VMY-induced cell 
death
To determine the role of p53 in VMY-induced cell 
death, an isogenic cellular system was established by 
using an adenoviral vector expressing p53shRNA to knock 
down p53 protein levels in LNCaP cells. As expected the 
p53-shRNA led to an approximate 50% reduction in p53 
protein levels relative to control vector cells (Fig. 2A). 
Additionally, p53 knockdown significantly inhibited 
(p<0.01) the cell death-promoting activity of VMY as 
measured by flow cytometry, and nearly completely 
abrogated PARP cleavage induced by this compound (Fig. 
2B). 
We next assessed the effects of expressing wild-
type p53 or p53 mutants in an isogenic cellular system, 
thus overcoming possible differences in the genetic 
background. The most common p53 mutations are 
missense mutations occurring in the DNA binding 
domain and include several “hot spot” codons, including 
R175, G245, R248, and R273. We performed transient 
transfection experiments in the p53-null PC3 cells 
using expression vectors for WT p53 or the previously 
characterized gain of function p53 mutation, p53-G245A, 
[13, 33] (Fig. 3A). The expression of wild-type p53 
decreased slightly the percent cell death in the presence 
of DMSO while mutant p53 expression had no effect. 
Consistent with our previous data (reference 26 and Fig. 
2), we found that p53 negative PC3 cells are insensitive to 
VMY-induced cell death. Most importantly, the expression 
of wild-type p53 but not the p53-G245A mutant restored 
VMY sensitivity in these cells, leading to a progressive 
and dose dependent increase in the subG1 population. 
These results firmly establish wild-type p53 as a key 
effector of VMY-induced cytotoxicity 
Compounds that rescue wild-type activity of 
mutant p53 proteins restore sensitivity to VMY
Several small molecules including PRIMA-1 have 
been developed that are capable of restoring the wild-
type conformation and function of mutant p53 proteins. 
PRIMA-1 acts via the formation of adducts with thiols 
contained within p53 that can rescue the biological activity 
of mutant forms of p53 [34]. We therefore determined 
whether PRIMA-1 could restore sensitivity to VMY in 
mutant p53 PCa cells. Treatment of the mutant p53P223L/
V274F DU145 human prostate cancer cell line with either 
VMY or PRIMA-1 alone showed only modest expression 
of the known down-stream p53 target gene, p21CIP1/WAF1, 
Figure 1: VMY activity in multiple cancer cell lines. (A) The p53 status as well as the percent increases in the SubG1 and G2/M 
subpopulations of cells treated with 30 uM VMY for 18hrs versus DMSO are shown. Changes in cell cycle profile were assessed by flow 
cytometry. LnCaP and MCF7 cells and DU145 and MDAMB231cells were used  as positive and negative controls, respectively, for VMY 
induction of cell death as previously reported [26, 28]. (B) Western blot establishing the induction of p53 protein levels by exposure to 30 
uM VMY for 18hrs in the p53 wild-type human cell lines, A172 and COLO357 but not in the p53 mutant cell line T98G. LnCaP cells were 
used as a positive control for p53 induction as previously shown [26]. (C) Annexin V positivity as measured by flow cytometry on cells with 
wild-type or compromised p53 (comp. p53) followed by exposure to DMSO or 30 uM VMY for 18hrs (* 40 hours for A172). PCa, prostate 
cancer, Pheo, pheochromocytoma, GBM, glioblastoma multiforme, BCa, breast cancer, PanCa, pancreatic cancer. 
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Figure 2: Knockdown of p53 blocks VMY-induced cell death. LNCaP cells were infected with control or p53-shRNA adenovirus 
and incubated for 72 hrs followed by treatment with either DMSO or 30 uM VMY for 18hrs. (A) An approximate 50% reduction in p53 
protein levels was observed (see inset, images are from the same autoradiogram and at the same exposure time). Cell death was significantly 
reduced in the p53shRNA treated cells as measured by trypan blue dye exclusion (*, p <0.01, N=3). (B) The effect of p53shRNA on the 
apoptotic machinery was confirmed by western blotting for p53 induction and for both full-length PARP (PARP-FL) and the long form of 
cleaved PARP (PARP-L, arrow). 
Figure 3: Expression of wild-type p53 but not mutant p53 restores VMY sensitivity. (A) p53-null PC3 prostate cancer cells 
were transiently transfected with wild-type p53, p53-G245A or empty vector control. Cell viability was measured by trypan blue dye 
exclusion 18 hrs after treatment with VMY or purvalanol B (PVB) at the concentrations shown. (B) Western blots were performed for both 
p53 and for p21CIP1/WAF1 (p21) on extracts from PRIMA-1 and vehicle-control treated DU145 cells with or without 18 hrs exposure to 30uM 
VMY. (C) DU145 cells were treated with 75 uM PRIMA-1 and VMY or PVB for 18 hrs. Cell viability was measured by trypan blue dye 
exclusion (*, p<0.05, vs PRIMA-1 plus DMSO). (D) Western blots for p53 and the full-length PARP protein (PARP-FL) and the long form 
of activated, cleaved PARP (PARP-L). β-actin was used as a loading control. Western blotting was performed on extracts derived from the 
cells used in the experiments shown in panel C.
Oncotarget10682www.impactjournals.com/oncotarget
while co-treatment with both PRIMA-1 and VMY led to 
the induction of p21CIP1/WAF1, without affecting the total p53 
expression levels, thus demonstrating restoration of p53 
activity by PRIMA-1 (Fig. 3B). Importantly, co-treatment 
with PRIMA-1 and VMY significantly increased cell death 
(Fig. 3C) and induced PARP cleavage (Fig. 3D) versus 
either PRIMA-1 or VMY alone. All extracts were run on 
the same gel and the image is from one representative 
autoradiogram. PRIMA-1 treatment alone did not 
significantly affect sensitivity to VMY in either LNCaP 
(p53wt) or PC3 (p53-null) cells (Supplemental Fig. S1), 
thus demonstrating the specificity of this compound in 
restoring VMY-mediated cell death to mutant p53 prostate 
cancer cells. 
VMY induces autophagy in LNCaP cells
As inhibition of apoptosis with caspase 8 or 9 
inhibitors failed to completely rescue VMY-induced cell 
death in LNCaP cells, despite a significant reduction in 
annexin V positivity (Fig. 4), we explored the role of 
autophagy in VMY-induced cell death. Autophagy was 
assessed by immuno-fluorescence and immuno-blot 
assays. The fluorescent and lysosomotropic compound 
Acridine Orange (AO) becomes protonated in the acidic 
environment of lysosomes and autophagosomes when 
autophagy is activated, resulting in its aggregation 
and accumulation. Protonated AO is identifiable via 
fluorescence microscopy as discrete aggregates that emit 
fluorescence at 640 nm, versus fluorescence at 525 nm in 
its native state. LNCaP cells were exposed to AO either 
in the presence or absence of VMY. VMY treatment 
resulted in the appearance of discrete acidic vesicles. We 
found that VMY-treated LNCaP cells exhibited a stark 
increase in discrete acidic vesicles with greater than 75% 
of the cells being AO positive, with an average of 10 AO 
puncta dispersed throughout the cytoplasm (Fig. 5A), 
thus demonstrating that VMY induces autophagosome 
formation. In contrast, in the few DU145 and PC3 cells 
that were AO positive (approximately 1%), on average 
only one AO puncta per cell was observed in DU145 cells 
and an average of two AO puncta were seen in PC3 cells 
(Fig. 5A) 
We next studied the pattern of subcellular 
localization of LC3-I (microtubule-associated protein 
1 light chain 3), which becomes lipidated by the class 
III phosphoinositide 3-kinase Vps34 when autophagy 
is activated and re-localizes from the microtubules to 
autophagosomal membranes (reviewed in Kang, et al. 
[35]). LNCaP, DU145 and PC3 cells were transiently 
transfected with an LC3-GFP expression vector [36] and 
subjected to fluorescence microscopy. VMY treatment 
induced LC3-GFP re-localization and concentration into 
prototypical autophagic puncta (Fig 5B, top right panel) 
in 11% of the LNCaP cells (with approximately 5 puncta 
per LC3 GFP positive cell) versus approximately 1% of 
VMY treated DU145 or PC3 cells with approximately 1 
puncta per LC3 GFP positive cell (Supplemental Fig. S2). 
Treatment with VMY and 3-methyl adenine (3-MA), a 
class III phosphoinositide 3-kinase inhibitor, resulted in 
a loss of LC3-GFP puncta in LNCaP cells (Fig. 5B lower 
left panel, average 0.8 puncta per cell) while chloroquine, 
which inhibits the fusion of autophagosomes with the 
lysosomes, lead to an increase in the number of positive 
cells (20%) and an increase in the number of puncta per 
cell (average of more than 8 puncta per cell) (Figure 5B, 
lower right panel) while treatment of PC3 and DU145 
cells these compounds had little effect (Supplemental Fig. 
S3).
Besides influencing LC3I subcellular localization, 
Fig 4: Effects of caspase inhibition on VMY-induced cell death. Single and dual inhibition of caspases 8 and 9 was performed. 
LnCAP cells were pretreated with 20 uM of the caspase 8 inhibitor Z-IETD-FMK (Casp 8 Inhibitor), the caspase 9 inhibitor Z-LEHD-FMK 
(Casp 9 Inhibitor) or both, followed by treatment with 30 uM VMY for 18 hrs. (A) Cell viability as assessed by trypan blue dye exclusion. 
(B) The proportion of cells undergoing apoptotic cell death as assessed using annexin V staining and measured by flow cytometry. *, p< 
0.05
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lipidation also alters LC3-1 electrophoretic mobility 
and which is referred to as LC3-II. Treatment of LNCaP 
cells with VMY for 24 hours resulted in an induction of 
conversion of LC3-I to LC3-II (Fig. 5C). Degradation of 
the autophagic receptor sequestosome1/p62 [37], together 
with its autophagic cargo, occurs via the lysosomes during 
autophagy. Accordingly, treatment with VMY for 24 hrs 
resulted in a decrease in p62 levels, (Fig. 5C). Collectively, 
these data clearly suggest that treatment of LNCaP cells 
with VMY results in an induction of autophagy.
VMY induces autophagic cell death in LNCaP 
cells
A static assessment of LC3 conversion fails 
to clearly indicate whether autophagy is inhibited or 
activated. To investigate how VMY affects autophagic 
flux [38], we performed dynamic kinetics experiments 
where autophagic induction was studied as a function of 
time following VMY treatment (Fig. 6). In the absence 
of VMY, the conversion of LC3-I to LC3-II remained 
relatively stable, with or without 3-MA, and increased 
slightly after exposure to chloroquine (Supplemental Fig. 
S3). This result strongly suggests that LNCAP cells have 
a relatively low rate of basal autophagic flux, at least in 
the absence of VMY. By contrast, treatment with VMY 
Figure 5: VMY induces autophagic activation in LNCaP cells. (A) Photomicrographs of LNCaP, PC3 and DU145 cells stained 
with acridine orange (AO) and treated for 18 hrs with DMSO (top row, LNCaP) or 30 uM VMY (bottom rows). The cells were imaged on 
a Zeiss LSM510 Meta microscope using a 488 nm dichroic mirror and a 525/50 bandpass filter to visualize cytoplasmic- and membrane- 
associated AO (green, left panels) and a 700 nm short pass filter using a metadetector of 651/42 emission filter to visualize protonated 
AO in acidic vesicles (orange, middle panels) and as merged images (green and orange, right panels). (B) LNCaP cells were transiently 
transfected with LC3-GFP and treated with DMSO (top left) or VMY (top right) in the presence or absence of 5 uM 3-MA (an inhibitor 
of early autophagy, lower left) or 50 uM chloroquine (an inhibitor of acidification of lysosomes and autophagosomes, lower right). (C) 
Authophagy time-course experiments performed on LNCaP cells treated with 30 uM VMY for 4, 6 and 24 hrs. Western blotting was 
performed to determine the levels of the autophagic cargo receptor, p62 (arrow) and for the relative abundance of LC3I and LC3II (double 
arrow). β-actin was used as a loading control.
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resulted in a strong induction of LC3-II conversion, as 
expected (see Fig 5 above), which was blocked by the 
early autophagy inhibitor 3-MA (Fig. 6A,B (blue line)), 
and was enhanced by chloroquine (Fig. 6A,B (red line). 
Importantly, inhibition of autophagy led to an overall 
reduction in cell death induced by VMY, as measured by 
trypan blue dye exclusion (Fig. 6C), indicating that the 
activation of autophagy is a central mechanism in VMY-
induced cell death.
VMY-induced autophagy is p53-dependent
In order to establish whether p53 mediates VMY-
induced autophagy, we infected LNCaP cells with a 
previously validated p53 shRNA-expressing lentivirus 
[39]. p53 shRNA led to an appreciable (greater than 60%) 
reduction of p53 protein levels compared with vector 
control (Fig. 7A). VMY failed to activate autophagy in 
the p53 shRNA-transduced cells, as demonstrated by the 
Figure 6: Temporal profile of autophagy induction in LNCaP cells by VMY. An extensive assessment of autophagic progression 
was performed at the times indicated in the presence or absence of the autophagy inhibitors 3-methyladenine (3-MA) and chloroquine 
(CQ). (A) Induction of autophagy was assessed following treatment with 30 uM VMY. (B) Quantification of normalized protein levels for 
LC3-II conversion was performed using the protein expression data in DMSO control treated cells (see Supplemental Fig. S2), following 
normalization to β-actin, allowing the effects of VMY and the independent effects of DMSO, 3-MA or CQ to be directly compared based 
on the results seen in A. The data were plotted as fold change in LC3-II. (C) Effect of inhibition of autophagy on VMY-induced cell death. 
The fold-increase in cell death induced by VMY in LNCaP cells in the presence or absence of 3-MA or chloroquine was quantified by 
trypan blue dye exclusion (* p < 0.01, N=3).
Figure 7: Genetic silencing of p53 inhibits the autophagic response to VMY. (A) LNCaP cells were infected with the empty 
lentivirus control or with the lentivirus p53-shRNA and treated with either DMSO or 30 uM VMY for 18hrs. Western blots were probed for 
levels of p53 and for LC3-I and LC3-II with β-actin used as a loading control. The arrow highlights the loss of conversion of LC3I to LC3-
II, commensurate with p53 knockdown. (B) LNCaP cells infected with the control or p53-shRNA lentivirus’s used in panel A and treated 
for 18 hrs with DMSO (left panels) or 30 uM VMY (right panels) and stained with AO. The AO treated cells were imaged as in Figure 5, 
and are shown as cytoplasmic- and membrane-associated AO (green, left panels) and as merged images to visualize both cytoplasmic- and 
membrane-associated AO and protonated AO in acidic vesicles (green and orange, right panels).
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lack of conversion of LC3-I to LC3-II (Fig. 7A, arrow). 
The knockdown of p53 reduced vesicular acidification 
by VMY (Fig. 7B lower right panel) compared to vector 
control cells (Fig. 7B upper right panel). Thus, p53 
regulates autophagosome formation and functional p53 
is required for VMY’s induction of autophagy in prostate 
cancer cells.
VMY impedes the proliferative capacity of 
primary prostate cancer cells derived from 
patients
We have recently reported on a novel cell culture 
approach that conditionally induces an indefinite 
proliferative state in primary mammalian epithelial cells 
[23-25, 40, 41], which are referred to as conditionally 
reprogrammed cells (CRCs). Prostate cancer CRC lines 
and their matched normal counterparts were established 
from two Gleason’s grade 7 patients who underwent 
radical prostatectomy at Massachusetts General Hospital 
and Georgetown University Hospital. Exposure to 
Figure 8: Effects of VMY on prostate cancer conditionally reprogrammed cells (CRCs). (A) The prostate cancer-derived 
CRCs from Patient 1 were treated with 30 um VMY for 18 hrs and western blotting performed, establishing the induction of p53 protein 
levels, consistent with results seen in p53 wild-type cell lines (left). The time course of induction of LC3II conversion following treatment 
with VMY (right). (B) Photomicrographs of cancer CRCs from Patient 1 stained with acridine orange (AO) and treated with DMSO (left 
panels) or 30 uM VMY (right panels). The AO treated cells were imaged as in Figure 5 and shown merged to visualize cytoplasmic- 
and membrane-associated AO as well as protonated AO in acidic vesicles (green and orange, top panels) and for only cytoplasmic- and 
membrane-associated AO (green, bottom panels). (C) Knockdown of p53 (p53shRNA) in the CRCs from Patient 1 by p53-shRNA lentivirus 
followed by treatment with 30 uM VMY for 18hrs. LNCaP cells were used as a positive control. Western blotting for p53 and β-actin is 
shown, confirming p53 knockdown. (D) Vector control (top) and p53-shRNA knockdown CRCs (bottom) from Patient 1 were treated with 
DMSO (left) or 30 uM VMY (right) for 18 hrs, stained with AO and the images merged to visualize cytoplasmic- and membrane-associated 
AO as well as protonated AO (green and orange).
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VMY for 18hrs established that the tumor CRCs were 
significantly more sensitive to VMY-induced cell 
death, compared to the patient-matched normal CRCs, 
(Supplemental Fig. S4). Cell cycle progression and 
apoptosis as measured by flow cytometry were also 
affected (Supplemental Fig. S4). Robust increases in the 
p53 protein levels were seen following VMY exposure 
(Fig. 8A), and VMY induced the conversion of LC3I to 
LC3II by 18hrs versus both early time points and DMSO 
alone (Fig 8A). In addition, sequencing of the p53 DNA 
binding domains of both CRC lines revealed no genetic 
mutations, further confirming that the p53 genes were 
indeed wild-type.
VMY also increased the protonated AO 
fluorescence, with discrete vesicles being observed 
throughout the cytoplasmic compartment in both 
CRC lines (Fig. 8B and Supplemental Fig. S5), fully 
recapitulating our observations in wild-type p53 LNCaP 
cells. Therefore, to establish whether VMY induction of 
p53 induces autophagy in prostate cancer CRCs, genetic 
silencing of p53 by shRNA was next performed. Lentiviral 
infection of the CRCs was carried out as described above 
and transduction with the p53shRNA virus resulted in 
significant reductions in p53 levels in the CRCs (Fig. 
8C-left). LNCaP cells were used as a positive control for 
p53 knockdown (Fig. 8C-right). The genetic silencing 
of p53 by shRNA significantly reduced VMY-induced 
vesicular acidification (Fig. 8D, upper right panel vs. lower 
right panel). These results strongly indicate that the loss of 
p53 abolishes VMY-induced autophagosome formation in 
primary prostate cancer cells following treatment.
Taken together, these experiments demonstrate that 
wild-type p53 is required for VMY-induced autophagy and 
apoptosis in both transformed cell lines and in primary 
prostate cancer cells and that VMY-induced cell death is 
dependent upon p53-driven autophagy.
DISCUSSION
Apoptosis and autophagy represent two complex and 
partially overlapping mechanisms that are activated under 
a variety of cell conditions, including chemotherapeutic 
stress (see references [38, 42] among others), and where 
p53 can play a significant regulatory role. For example, 
the initiation of p53 and apoptosis by chemotherapeutic 
drugs often results in cell death. Furthermore, while 
we have recently discovered that autophagy is the key 
pathways for degrading mutant p53 proteins [20], it is 
autophagy per se that plays a central role in stabilizing 
wild-type p53 following DNA damage [17]. Additionally, 
autophagy-related proteins such as Beclin 1, ATG5 [19, 
43] and Ambra1 [44] are not only targets of apoptosis 
but also reciprocally influence apoptotic activity. And, 
while controlled autophagy can function as a pro-survival 
mechanism [45], unchecked autophagy can trigger cell 
death. We predict therefore that compounds that can 
support p53 induction and both unchecked autophagy and 
robust apoptosis will deliver increased curative effects. 
We had previously reported that VMY induced both 
p53 protein levels and phosphorylation on serine residues 
15, 46 and 393, as well as increasing both p21CIP1/WAF1 levels 
and PARP cleavage [26], suggesting that p53 activity may 
transduce at least a component of VMY’s effects, however 
this possibility was not directly addressed. Using genetic 
and chemical approaches, we herein established that wild-
type p53 plays an essential role in inducing both apoptosis 
and autophagy in prostate cancer cells. While there is 
known crosstalk between autophagy and apoptosis, as 
they share certain signaling pathways and proteins, the 
mechanisms by which this bridging occurs have not been 
fully defined. Furthermore, p53’s role in concurrently 
regulating apoptosis and autophagy differs by cell type 
and can be influenced by the type of stressor to which the 
cell is exposed. For example, treatment of SiHa (cervical 
cancer), A549 (lung) and MCF7 (breast) cancer cells 
with docosahexaenoic acid resulted in autophagy via an 
induction of AMPK and mTOR inhibition [46]. However 
while inhibition of autophagy partially prevented the 
apoptotic response, the loss of p53 was required [46]. In 
contrast, we show that the induction of p53 by VMY was 
a prerequisite for inducing both autophagy and apoptosis, 
and that silencing p53 effectively blocked activation of 
both pathways. While further studies will be required to 
more fully elucidate the molecular mechanisms associated 
with p53’s sensitivity to VMY, these studies underscore 
the complexity of both p53’s role in regulating cellular 
responses to treatment and highlight the importance that 
the model system plays in both drug development and 
predictive modeling of therapeutic responses. 
The lack of clinically relevant cell lines has had a 
major impact on effective therapeutic development [47, 
48]. By combining detailed tissue collection and pathology 
with our CRC technology [22-25, 40, 41], we generated 
two wild-type p53 prostate CRC lines from Gleasons 
score 7 patients. Since the mechanisms by which p53 
bridges autophagy and apoptosis to induce cell death are 
still not fully elucidated, these CRC cultures represent 
important resources for the assessment of p53 activity in 
non-transformed prostate cells. For example, we anticipate 
that prostate cultures derived from local or distant 
metastases will contain cells harboring mutant p53 genes 
[30]. In addition, the establishment of isogenic cell lines 
derived through the use of gene-targeting vectors and/or 
viral delivery of shRNAs will allow for the modification 
of single or multiple genes in either normal or tumor 
CRCs with minimal impacts on their existing genetic 
background. Since cultures of CRCs can be established 
via single cell cloning from the primary tissue sample 
(CA, XL, RS unpublished), the necessary tools now 
exist for the in-depth study of p53 function in a highly 
biologically relevant and patient-specific model system. 
In addition, the CRC approach allows for the study of 
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inter- and intra- tumor heterogeneity with unprecedented 
accuracy and detail and will hopefully form the working 
basis for a more personalized approach to prostate cancer 
therapy, analogous to the patient we successfully treated 
for malignant recurrent respiratory papillomatosis, a life 
threatening cancer of the airway epithelium [24]. 
In conclusion, we have identified a small molecule-
inducible, p53-dependent link to the induction of 
apoptosis, autophagy and cell death in prostate cancer 
cells. Interestingly, the co-expression of the p53G245A 
mutant protein in LNCaP cells failed to interfere with 
VMY-induced cell death (CA, MA, LR data not shown), 
suggesting that tumors that are heterozygous for mutant 
p53 still retain VMY sensitivity. While VMY has not 
been tested to date in humans, our mouse imaging studies 
established that VMY (20 mg/kg given three times per 
week for more than four weeks,) was both an effective 
treatment for sporadic medulloblastoma and importantly 
was well tolerated, with no signs of toxicity being found 
[29]. Furthermore the straightforward mass spectrometry-
based method we developed in that study for quantifying 
systemic VMY delivery to tissues, including the prostate 
[29], will be useful in facilitating future in vivo efficacy 
and molecular mechanism studies using both engineered 
mouse models and primary human tissue xenografts. Since 
PRIMA-1 resensitized p53-mutant cells to VMY-induced 
cell death, we conclude that this compound may be highly 
effective in treating a broad array of cancers, including 
those with p53 mutations. Finally, similar to our recent 
studies [24, 41], the ability to now perform direct testing of 
the efficacy of VMY as a monotherapy or in combination 
with other drugs on individual patients cells may result in 
more rapidly achievable and more accurate predictions of 
a patient’s response to therapeutic intervention, resulting 
in better outcomes and enhanced survivorship. 
METHODS
Cell lines and cell culture
All commercial cell lines were obtained from 
the ATCC. The human cancer cell lines LNCaP, PC3, 
AsPC1, PC12 and COLO-357 were maintained in 
RPMI containing 10% FBS, 1mM sodium pyruvate, 
and 100 U/ml Penicillin-Streptomycin. The cell lines 
DU145, MCF7, MDA-MB231, MIA-PACA and A172 
were maintained in DMEM media containing 10% FBS, 
L-glutamine, and 100 U/ml Penicillin-Streptomycin. T98G 
cells were maintained in Eagle’s Minimum Essential 
Media containing 10% FBS, L-glutamine, and 100 U/ml 
Penicillin-Streptomycin. Human radical prostatectomy 
samples were collected under the auspices and approval 
of the Georgetown University and Massachusetts General 
Hospital Institutional Review Boards. Following detailed 
pathological analyses that documented that the tissue 
sections collected were nearly exclusively tumor cells, 
the specimens were processed via protease dissociation 
as previously described [23]. Primary cultures were 
established at Georgetown using the CRC method as 
previously described [23]. For experimentation, the cells 
were carried in conditioned media as described [25]. 
Briefly, irradiated J2 feeder cells were plated in 175 cm2 
tissue culture flasks (BD Biosciences, Franklin Lakes, NJ) 
in 30 mls of F media. The media was collected after three 
days in culture and centrifuged at 1000 x g for 5 minutes at 
4°C to remove cellular debris, followed by filtration using 
a 0.22 µm Millex-GP filter unit (Millipore, Billerica, MA). 
For cell culture, three volumes of conditioned F media was 
mixed with one volume of fresh F medium and the final 
working conditioned media was supplemented with 5 µM 
Y-27632.
Flow cytometry
The prostate cells were fixed and stained with 20ug/
ml propidium iodide (PI) and 5 U RNase A, and the DNA 
content and SubG1 DNA fragmentation was measured 
using a FACStar Plus system (Becton-Dickson, Franklin 
Lakes, NJ) as previously described [26, 27]. Cellular 
apoptosis was also assessed by APC-Annexin V antibody 
(Biolegend, San Diego, CA) staining immediately after 
treatment with VMY and analyzed using FACStar Plus 
dual laser FACSort system (Becton-Dickson, Franklin 
Lakes, NJ) as previously described by us [26, 27, 49, 50]. 
Immunoblotting
Protein extracts were separated on 4-20% Tris-
glycine gels and electro-blotted onto PVDF membranes 
as previously described [13, 26, 27]. Protein levels 
were assessed using antibodies against p53 (Millipore, 
#05-224), PARP (Cell Signaling, Danvers, MA #9542), 
b-actin (Cell Signaling, Danvers, MA #4967), p21 (Santa 
Cruz #SC 756), LC3B (Cell Signaling, Danvers, MA 
#3868S) and P62 (Cell Signaling, Danvers, MA #5114S) 
Densitometry was performed using ImageJ analysis 
software (NIH, Bethesda, MD) as previously described 
[13, 26, 27]. 
Cell viability and growth
Cell viability was determined using trypan blue 
dye exclusion and viable and total cell counting using a 
hemocytometer as previously described [26, 27].
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p53 expression and shRNA knockdown
The p53 wild-type and p53G245A mutant vectors, 
have been previously described by us [14, 51]. For 
adenovirus knockdown experiments, Adp53shRNA and 
empty vector control virus were purchased commercially 
(Vector Biolabs, Philadelphia, PA, #1854) and used as 
described by the manufacturer. For lentivirus-based 
p53 knockdown experiments, the pLKO-p53shRNA 
and empty vector lentivirus vectors (kindly provided by 
Todd Waldman, Georgetown University) were used as 
described [39]. Briefly, 293T cells (ATCC, Manassas, VA) 
were cotransfected with shRNA constructs along with the 
pHR′8.2ΔR and pCMV-VSV-G helper constructs. After 
24 hours, the media was changed and the virus-containing 
media was harvested after an additional 24 hours of 
incubation. The prostate cancer cells were seeded at 30% 
confluency and viral infections were performed for 72 
hours prior to treatment with VMY or DMSO. Efficiency 
of the knockdown was monitored by p53 immunoblotting 
as previously described [14, 26, 51]. 
p53 restoration
DU145 cells were pre-treated with 75µM PRIMA-1 
(Sigma, St Louis, MO) for 24hrs prior to treatment. 
Activity of PRIMA-1 was monitored via assessing the 
induction of p21CIP1/WAF1 (Santa Cruz, sc481) protein levels 
by immunoblot. 
Autophagy and Apoptosis Inhibitors. 
For the autophagy inhibition, 3-methyladenine (3-
MA) (Sigma, St Louis, MO M921) was used at 5mM 
and 10 mM concentrations and chloroquine diphosphate 
(Sigma, St Louis, MO) was used at 50 µM and 100 µM. 
Cells were exposed to these inhibitors for 20 minutes prior 
to treatment with either DMSO or VMY.
The caspase 8 inhibitor Z-IETD-FMK, (Sigma, St 
Louis, MO) and the caspase 9 inhibitor Z-LEHD-FMK 
(Sigma, St Louis, MO) were resuspended in DMSO and 
used at final concentrations of 20uM.
Autophagic vesicle maturation. 
Autophagic vesicle maturation was analyzed by 
the detection of acidic vesicular organelles and LC3-GFP 
localization. For both the experiments, LNCaPs, DU145 
and PC3 cell lines were analyzed.
In order to detect the acidic vesicles in presence 
or absence of VMY treatment, the cells were stained 
with acridine orange (AO). Briefly, the cells were grown 
overnight on World Precision Instruments 35 mm glass 
Fluorodish cell culture dish (Fisher Scientific, Waltham, 
MA) in appropriate media. After an 18 hr incubation 
with 30 µM VMY, the AO solution was added at a final 
concentration of 10 µM, and the cells were incubated 
for 20 minutes at 37ºC. Live cells were imaged on a 
Zeiss (Thornwood, NY) LSM510 Meta microscope
.
 
Non-protonated AO (green fluorescence) was imaged 
using argon 488 laser and a 488 dichroic mirror and a 
525/50 bandpass filter. For the protonated (orange/red 
fluorescence) species of AO, a multi-photon chameleon 
laser was set to 760 with a 700 short pass filter using a 
651/42 emission filter. LC3 translocation was detected 
using the green fluorescent protein (GFP)-fused LC3 
construct that was generously donated by Dr Robert 
Clarke [36]. Briefly, cells were seeded in 6 well plates 
contained glass coverslips and allowed to attach overnight. 
14 ug of LC3-GFP expression plasmid were transfected 
using Lipofectamine LTX reagent (Life Technologies, 
Carlsbad, CA) as previously described [36]. 24 hours 
after transfection, the cells were pretreated or not with 
5uM 3MA or 50 uM Chloroquine for 20 minutes and 
further treated with VMY or vehicle. After 18 hours, the 
coverslips with attached cells were stained with DAPI and 
rinsed 3 times with PBS. The excess buffer was removed 
and the coverslips were mounted. Imaging was performed 
by confocal microscopy as previously described [27]. 
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